Pioglitazone Suppresses CXCR7 Expression to Inhibit Human Macrophage Chemotaxis through Peroxisome Proliferator-Activated Receptor γ

Biochemistry

Volumn 54, Issue 45, 2015, Pages 6806-6814

  Zhao, Duo ^a   Zhu, Zhicheng ^a   Li, Dan ^a   Xu, Rihao ^a   Wang, Tiance ^a   Liu, Kexiang ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; CHEMICAL ACTIVATION; CYTOLOGY; DISEASES;

ATHEROSCLEROTIC LESIONS; CARDIO-VASCULAR DISEASE; CELL VIABILITY; HUMAN MACROPHAGES; MACROPHAGE DIFFERENTIATIONS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; THIAZOLIDINEDIONES; TYPE 2 DIABETES MELLITUS;

MACROPHAGES;

CHEMOKINE RECEPTOR CXCR7; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; 2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BENZAMIDE DERIVATIVE; CHEMOKINE RECEPTOR CXCR; CXCR7 PROTEIN, HUMAN; PYRIDINE DERIVATIVE; ROSIGLITAZONE; SMALL INTERFERING RNA;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL VIABILITY; CHEMOTAXIS; CLINICAL ARTICLE; HUMAN; HUMAN CELL; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGONISTS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CAROTID ARTERY DISEASES; CAROTID ENDARTERECTOMY; CELL CULTURE; CHEMICAL PHENOMENA; COMPLICATION; DIABETES MELLITUS, TYPE 2; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; RNA INTERFERENCE;

BENZAMIDES; CAROTID ARTERY DISEASES; CELL DIFFERENTIATION; CELLS, CULTURED; CHEMOTAXIS; COMBINED MODALITY THERAPY; DEPRESSION, CHEMICAL; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; ENDARTERECTOMY, CAROTID; GENE EXPRESSION REGULATION; HUMANS; MACROPHAGES; PPAR ALPHA; PPAR GAMMA; PYRIDINES; RECEPTORS, CXCR; RNA INTERFERENCE; RNA, SMALL INTERFERING; THIAZOLIDINEDIONES;

EID: 84947285546     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/acs.biochem.5b00847     Document Type: Article

References (36)

1. Haffner, S. M., Lehto, S., Ronnemaa, T., Pyorala, K., and Laakso, M. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N. Engl. J. Med. 339, 229-234 10.1056/NEJM199807233390404
2. Stern, M. P. (1995) Diabetes and cardiovascular disease. The "common soil" hypothesis Diabetes 44, 369-374 10.2337/diab.44.4.369
3. Lincoff, A. M., Wolski, K., Nicholls, S. J., and Nissen, S. E. (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials Jama 298, 1180-1188 10.1001/jama.298.10.1180
4. Levi, Z., Shaish, A., Yacov, N., Levkovitz, H., Trestman, S., Gerber, Y., Cohen, H., Dvir, A., Rhachmani, R., Ravid, M., and Harats, D. (2003) Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model Diabetes, Obes. Metab. 5, 45-50 10.1046/j.1463-1326.2003.00240.x
5. Li, A. C., Brown, K. K., Silvestre, M. J., Willson, T. M., Palinski, W., and Glass, C. K. (2000) Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice J. Clin. Invest. 106, 523-531 10.1172/JCI10370
6. Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., Kuriyama, H., Hotta, K., Nakamura, T., Shimomura, I., and Matsuzawa, Y. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein Diabetes 50, 2094-2099 10.2337/diabetes.50.9.2094
7. DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., Mack, W. J., Mudaliar, S., Ratner, R. E., Williams, K., Stentz, F. B., Musi, N., and Reaven, P. D. (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance N. Engl. J. Med. 364, 1104-1115 10.1056/NEJMoa1010949
8. Woollard, K. J. and Geissmann, F. (2010) Monocytes in atherosclerosis: subsets and functions Nat. Rev. Cardiol. 7, 77-86 10.1038/nrcardio.2009.228
9. Chi, Z. and Melendez, A. J. (2007) Role of cell adhesion molecules and immune-cell migration in the initiation, onset and development of atherosclerosis Cell adhesion & migration 1, 171-175 10.4161/cam.1.4.5321
10. Abi-Younes, S., Sauty, A., Mach, F., Sukhova, G. K., Libby, P., and Luster, A. D. (2000) The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques Circ. Res. 86, 131-138 10.1161/01.RES.86.2.131
11. Zernecke, A., Bot, I., Djalali-Talab, Y., Shagdarsuren, E., Bidzhekov, K., Meiler, S., Krohn, R., Schober, A., Sperandio, M., Soehnlein, O., Bornemann, J., Tacke, F., Biessen, E. A., and Weber, C. (2008) Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis Circ. Res. 102, 209-217 10.1161/CIRCRESAHA.107.160697
12. Wei, D., Wang, G., Tang, C., Qiu, J., Zhao, J., Gregersen, H., and Deng, L. (2012) Upregulation of SDF-1 is associated with atherosclerosis lesions induced by LDL concentration polarization Ann. Biomed. Eng. 40, 1018-1027 10.1007/s10439-011-0486-z
13. Burns, J. M., Summers, B. C., Wang, Y., Melikian, A., Berahovich, R., Miao, Z., Penfold, M. E., Sunshine, M. J., Littman, D. R., Kuo, C. J., Wei, K., McMaster, B. E., Wright, K., Howard, M. C., and Schall, T. J. (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development J. Exp. Med. 203, 2201-2213 10.1084/jem.20052144
14. Thelen, M. and Thelen, S. (2008) CXCR7, CXCR4 and CXCL12: an eccentric trio? J. Neuroimmunol. 198, 9-13 10.1016/j.jneuroim.2008.04.020
15. Naumann, U., Cameroni, E., Pruenster, M., Mahabaleshwar, H., Raz, E., Zerwes, H. G., Rot, A., and Thelen, M. (2010) CXCR7 functions as a scavenger for CXCL12 and CXCL11 PLoS One 5, e9175 10.1371/journal.pone.0009175
16. Levoye, A., Balabanian, K., Baleux, F., Bachelerie, F., and Lagane, B. (2009) CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling Blood 113, 6085-6093 10.1182/blood-2008-12-196618
17. Odemis, V., Lipfert, J., Kraft, R., Hajek, P., Abraham, G., Hattermann, K., Mentlein, R., and Engele, J. (2012) The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells Glia 60, 372-381 10.1002/glia.22271
18. Hartmann, T. N., Grabovsky, V., Pasvolsky, R., Shulman, Z., Buss, E. C., Spiegel, A., Nagler, A., Lapidot, T., Thelen, M., and Alon, R. (2008) A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells J. Leukocyte Biol. 84, 1130-1140 10.1189/jlb.0208088
19. Ma, W., Liu, Y., Wang, C., Zhang, L., Crocker, L., and Shen, J. (2014) Atorvastatin inhibits CXCR7 induction to reduce macrophage migration Biochem. Pharmacol. 89, 99-108 10.1016/j.bcp.2014.02.014
20. Ma, W., Liu, Y., Ellison, N., and Shen, J. (2013) Induction of C-X-C chemokine receptor type 7 (CXCR7) switches stromal cell-derived factor-1 (SDF-1) signaling and phagocytic activity in macrophages linked to atherosclerosis J. Biol. Chem. 288, 15481-15494 10.1074/jbc.M112.445510
21. Ishibashi, M., Egashira, K., Hiasa, K., Inoue, S., Ni, W., Zhao, Q., Usui, M., Kitamoto, S., Ichiki, T., and Takeshita, A. (2002) Antiinflammatory and antiarteriosclerotic effects of pioglitazone Hypertension 40, 687-693 10.1161/01.HYP.0000036396.64769.C2
22. Nguyen, M. T., Chen, A., Lu, W. J., Fan, W., Li, P. P., Oh, D. Y., and Patsouris, D. (2012) Regulation of chemokine and chemokine receptor expression by PPARgamma in adipocytes and macrophages PLoS One 7, e34976 10.1371/journal.pone.0034976
23. Yamashita, K., Murakami, H., Teruaki, O., and Motohashi, M. (1996) High-performance liquid chromatographic determination of pioglitazone and its metabolites in human serum and urine J. Chromatogr., Biomed. Appl. 677, 141-146 10.1016/0378-4347(95)00440-8
24. Cariou, B., Charbonnel, B., and Staels, B. (2012) Thiazolidinediones and PPARgamma agonists: time for a reassessment Trends Endocrinol. Metab. 23, 205-215 10.1016/j.tem.2012.03.001
25. Kumar, R., Tripathi, V., Ahmad, M., Nath, N., Mir, R. A., Chauhan, S. S., and Luthra, K. (2012) CXCR7 mediated Gialpha independent activation of ERK and Akt promotes cell survival and chemotaxis in T cells Cell. Immunol. 272, 230-241 10.1016/j.cellimm.2011.09.015
26. Berahovich, R. D., Zabel, B. A., Penfold, M. E., Lewen, S., Wang, Y., Miao, Z., Gan, L., Pereda, J., Dias, J., Slukvin, II, McGrath, K. E., Jaen, J. C., and Schall, T. J. (2010) CXCR7 protein is not expressed on human or mouse leukocytes J. Immunol. 185, 5130-5139 10.4049/jimmunol.1001660
27. Cho, Y. C., Kim, H. J., Kim, Y. J., Lee, K. Y., Choi, H. J., Lee, I. S., and Kang, B. Y. (2008) Differential anti-inflammatory pathway by xanthohumol in IFN-gamma and LPS-activated macrophages Int. Immunopharmacol. 8, 567-573 10.1016/j.intimp.2007.12.017
28. Welch, J. S., Ricote, M., Akiyama, T. E., Gonzalez, F. J., and Glass, C. K. (2003) PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages Proc. Natl. Acad. Sci. U. S. A. 100, 6712-6717 10.1073/pnas.1031789100
29. Chinetti, G., Fruchart, J. C., and Staels, B. (2003) Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function Curr. Opin. Lipidol. 14, 459-468 10.1097/00041433-200310000-00006
30. Rajagopal, S., Kim, J., Ahn, S., Craig, S., Lam, C. M., Gerard, N. P., Gerard, C., and Lefkowitz, R. J. (2010) Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7 Proc. Natl. Acad. Sci. U. S. A. 107, 628-632 10.1073/pnas.0912852107
31. Hanefeld, M. (2001) Pharmacokinetics and clinical efficacy of pioglitazone International journal of clinical practice Suppl.) 19-25
32. Goetze, S., Eilers, F., Bungenstock, A., Kintscher, U., Stawowy, P., Blaschke, F., Graf, K., Law, R. E., Fleck, E., and Grafe, M. (2002) PPAR activators inhibit endothelial cell migration by targeting Akt Biochem. Biophys. Res. Commun. 293, 1431-1437 10.1016/S0006-291X(02)00385-6
33. Goetze, S., Xi, X. P., Kawano, H., Gotlibowski, T., Fleck, E., Hsueh, W. A., and Law, R. E. (1999) PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells J. Cardiovasc. Pharmacol. 33, 798-806 10.1097/00005344-199905000-00018
34. Yang, J., Liu, C., Zhang, L., Liu, Y., Guo, A., Shi, H., Liu, X., and Cheng, Y. (2015) Intensive Atorvastatin Therapy Attenuates the Inflammatory Responses in Monocytes of Patients with Unstable Angina Undergoing Percutaneous Coronary Intervention via Peroxisome Proliferator-Activated Receptor gamma Activation Inflammation 38, 1415-1423 10.1007/s10753-015-0116-2
35. Bouhlel, M. A., Derudas, B., Rigamonti, E., Dievart, R., Brozek, J., Haulon, S., Zawadzki, C., Jude, B., Torpier, G., Marx, N., Staels, B., and Chinetti-Gbaguidi, G. (2007) PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties Cell Metab. 6, 137-143 10.1016/j.cmet.2007.06.010
36. Zhang, O. and Zhang, J. (2015) Atorvastatin promotes human monocyte differentiation toward alternative M2 macrophages through p38 mitogen-activated protein kinase-dependent peroxisome proliferator-activated receptor gamma activation Int. Immunopharmacol. 26, 58-64 10.1016/j.intimp.2015.03.005